Plasma fibroblast growthfactor-21 (FGF21) responses to acute alcohol exposure will be evaluated in three groups: A: 15 individuals diagnosed with alcohol dependence (ICD10 code F10.2) and no alcoholic liver diseases, B: 15 healthy individuals with one or two parents with alcohol dependence, and C: 15 healthy matched controls without history of or disposition to alcohol dependence. The experimental day consists of a load of 0.5 g ethanol per kg body weight ingested from time 0-10 minutes followed by a 7 h period in which blood will be sampled with frequent intervals, rating of preference for ethanol, salt, sour, bitterly and sweets, sensations of hunger, appetite, satiety, headache, and nausea will be evaluated using visuel analogue scale and resting energy expenditure will be evaluated using indirect calorimetry.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
45
Ethanol administration
Center for Clinical Metabolic Research, Gentofte Hospital
Hellerup, Denmark
Fibroblast growthfactor-21
Plasma FGF21 concentrations, a member of the endocrine FGF-family
Time frame: One year
Ethanol
Plasma ethanol concentration
Time frame: One year
Glucose
Plasma glucose concentrations
Time frame: One year
Insulin and C-peptide
Serum insulin and C-peptide concentrations
Time frame: One year
Glucagon
Plasma glucagon concentration
Time frame: One year
Tumor Necrosis Factor-alpha (TNF)
Plasma TNF-alpha concentrations
Time frame: One year
Lipopolysaccharide Binding Protein (LBP)
Plasma LBP concentrations
Time frame: One year
Interferon-gamma (INF)
Plasma INF-gamma concentrations
Time frame: One year
Interleukine-10 (IL-10)
Plasma IL-10 concentrations
Time frame: One year
Interleukine-8 (IL-8)
Plasma IL-8 concentrations
Time frame: One year
Interleukine-6 (IL-6)
Plasma IL-6 concentrations
Time frame: One year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.